Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

India Generic Drug Maker Matrix Increases Stake in China's Mchem

This article was originally published in PharmAsia News

Executive Summary

NEW DELHI - Hyderabad, India-based Matrix Laboratories has increased its stake in China-based Mchem group to 97 percent from 60 percent for an undisclosed amount, Matrix said

You may also be interested in...



Mylan Laboratories to Enter Japan's Generic Drug Market (Japan)

Mylan Laboratories Inc., the number three generic drug producer in the world, is working to break into Japan's generic market. Recently Mylan bought out the generic end of Germany's Merck KGaA. The Merck deal gave Mylan control of subsidiaries selling generics in 90 countries around the world. Among these companies is the Japan-based Merck Seiyaku Ltd. Mylan plans to work with Seiyaku to expand its generic business across the country, especially production of slow-release formulas, Mylan's specialty. Seiyaku will also team up with India's Matric Laboratories Ltd., which is also an affiliate of Mylan. The two companies will work together to expand Matrix's active pharmaceutical ingredient business in Japan. (Click here for more

List Ahead For Southeast Asia Pharma In 2015

PharmAsia News looks ahead at 2015 to highlight expected trends and events shaping the biomedical community in Southeast Asia.

Southeast Asia 2014: Distribution, Manufacturing To The Fore

Southeast Asia in 2014 saw a continued push by several nations in the region to ink a Trans-Pacific Partnership pact that would potentially have a major impact on biological drugs. Also manufacturing and distribution saw a leap in the hub of Singapore as governments in the region ramped-up health spending.

UsernamePublicRestriction

Register

ID1132679

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel